PMGC
Operates packaging and precision-machining businesses alongside early-stage technology programs.
Something off on this page? Send us feedback.
Profile
Sells custom protective packaging and high-tolerance contract machining through an acquisition-led diversified holding company that also owns preclinical bioscience and early-stage defense technology programs. Revenue comes from direct custom packaging sales and machining orders, repeat work, and referrals.
Combines custom protective packaging with precision engineering and machining, while also housing early-stage bioscience, defense-technology, and investment activities. Pacific Sun Packaging designs and manufactures electrostatic-discharge protective packaging for computer components. AGA Precision, SVM Machining, and A&B Aerospace provide high-tolerance CNC machining for aerospace, defense, and industrial customers. Operations and assets are principally in the United States, with manufacturing operations in California.
Generates operating revenue from customized packaging and contract machining, with repeat work, referrals, and customer purchase orders supporting the manufacturing businesses. NorthStrive Biosciences' muscle-preservation candidates remain preclinical, and NorthStrive Defense Tech's licensed autonomous-vehicle technology remains in prototype and simulation-validation stages. Recent acquisitions require integration, while revenue and purchases remain concentrated among a limited group of customers and suppliers.
Company facts
Key statistics
Year to date −99.6% · Average volume (30d) 64.2K
Analysts
No analyst consensus on record.
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 14, 2026Q2 FY26 | — | −$6.10 | — | — | $1.3M | — | +1.45% |
| May 14, 2026Q1 FY26 | — | −$11.21 | — | — | $682.0K | — | +0.97% |
| Mar 26, 2026Q4 FY25 | — | −$0.52 | — | — | $304.1K | — | −10.70% |
| Nov 14, 2025Q3 FY25 | — | −$19.80 | — | — | $285.9K | — | −1.70% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $285.9K | $304.1K | $682.0K | $1.3M | |
| Gross profit | −$15.4K | −$20 | $42.7K | $47.5K | $71.0K | $104.5K | |
| Operating income | −$1.2M | −$1.0M | −$2.2M | −$3.0M | −$3.3M | −$3.8M | |
| Net income | −$1.6M | −$562.4K | −$2.6M | −$3.0M | −$5.0M | −$2.9M | |
| Diluted EPS | −$2,480.50 | −$379.20 | −$1,178.40 | −$519.20 | −$111.70 | −$6.00 | |
| Gross margin | — | — | 14.9% | 15.6% | 10.4% | 8.0% | |
| Operating margin | — | — | -767.5% | -975.3% | -487.0% | -292.2% |
Fiscal years (4-quarter sums)FY22 $766.3K · FY23 $1.7M · FY24 −$605.5K · FY25 $590.1K
Balance sheet, Jun 30, 2026Cash & short-term investments $18.8M · Total debt $13.9M · Total assets $36.6M · Shareholders' equity $16.7M
Dividends
No dividends on record.
Ownership
Shares outstanding 454.4K · Float 409.0K · 90.0% free float
A split settled inside the quarter being compared, so quarter-on-quarter change is not shown.
Insider tradesForm 4
No open-market trades in the last 12 months.
View detailsPeers
- Ducommun
Aerospace and defense manufacturing rival for complex components.
- Howmet Aerospace
Scaled aerospace components and fasteners contest machining awards.
- UFP Technologies
Custom ESD protective packaging overlaps electronics-component shipping.
- Biohaven
Advanced myostatin-activin therapy targets fat loss and lean-mass gains.
- Scholar Rock
Anti-myostatin programs challenge the muscle-health therapeutic thesis.
- Novo Nordisk (ADR)
Wegovy and Ozempic dominate the GLP-1 obesity-treatment ecosystem.
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| PMGC | $5.42 | +1.21% | $2.4M | — | — | 0.9 | — |
| Ducommun | $176.30 | 0.00% | $2.66B | — | 36.1 | 3.1 | +11.0% |
| Howmet Aerospace | $265.80 | +0.39% | $105.97B | 57.1 | 45.5 | 11.6 | +24.1% |
| UFP Technologies | $300.05 | −0.05% | $2.32B | 32.4 | 29.7 | 3.7 | +15.1% |
| Biohaven | $15.16 | −1.56% | $2.32B | — | — | — | — |
| Scholar Rock | $57.80 | 0.00% | $6.93B | — | — | — | — |
| Novo Nordisk (ADR) | $45.60 | +0.00% | $202.54B | 11.2 | 18.4 | 4.0 | +0.0% |
| Median | 32.4 | 32.9 | 3.8 | +13.0% |








